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Abstract 
Introduction 
While a plethora of systematic reviews have provided evidence of efficacy, effectiveness 
and safety of direct-acting oral anticoagulants (DOACs) in the management of non-
valvular atrial fibrillation (AF), there has been little emphasis on clinicians’ perspectives. 
This systematic review aimed to critically appraise, synthesise and present the available 
evidence of clinicians’ views and experiences.  
Methods 
Studies published in English from January 2006 to July 2017 reporting the views and/or 
experiences of doctors, nurses or pharmacists on any individual DOAC or as a 
pharmacological group were included. Studies were assessed for quality by two 
researchers, data extracted and findings synthesised using a narrative approach.  
Results 
Following exclusion of duplicates, 777 titles, 394 abstracts and 196 studies were 
screened. Ten studies were included in the review, nine of which were quantitative 
(cross-sectional surveys) and one qualitative (semi-structured interviews), with marked 
heterogeneity in outcomes reported. Studies were conducted exclusively in Europe and 
the United States. In those studies reporting clinician preference, DOACs were first 
choice over warfarin in naïve patients, based on perceptions of evidence of effectiveness 
equivalent or superior to warfarin and superior safety. Other advantageous factors were 
in those with an unstable INR and likely to miss appointments. There were, however, 
concerns relating to management of over-anticoagulation and experiences of observed 
bleeding rates.  
Conclusion 
There is a limited evidence base of clinicians’ perspectives of DOACs, necessitating 
further research, particularly given the trajectory of increased use worldwide.  
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What is already known about this subject  
 There is a plethora of evidence, derived from systematic trials and meta-
analyses, of the efficacy, effectiveness and safety of DOACs 
 DOACs have surpassed warfarin as the oral anticoagulants of choice, particularly 
for the management of non-valvular AF 
What this study adds  
 There is a limited evidence base derived from nine surveys and one qualitative 
interview study 
 Clinicians’ views and experiences are still very unclear 
 There is a need for further robust and rigorous research on clinicians’ 
perspectives 
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Introduction 
Recent years have seen marked changes in the availability and prescription of oral 
anticoagulants worldwide. The introduction of dabigatran in to the United Kingdom (UK) 
market in 2008 was followed by rivaroxaban, apixaban and most recently edoxaban. 
While initially termed ‘new’ or ‘novel’ oral anticoagulants (NOACs), the International 
Society of Thrombosis and Haemostasis has suggested that ‘direct-acting oral 
anticoagulant (DOAC)’ be adopted universally [1]. This is more consistent with the 
pharmacotherapeutic classifications of direct thrombin inhibitors (dabigatran) or directed 
Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) [2].  
DOACs have now been incorporated into local, national and international prescribing 
guidance and policy statements. For example, the National institute for Health and Care 
Excellence (NICE), which provides national guidance and advice to improve health and 
social care in England and Wales, recommends use of all four DOACs as alternatives to 
warfarin in non-valvular atrial fibrillation [3]. DOACs are also recommended within atrial 
fibrillation management guidelines from the European Society of Cardiology [4], the 
American College of Cardiology/ American Heart Association Task Force on Practice 
Guidelines and the Heart Rhythm Society [5], and the recently updated 2018 Practical 
Guide from the European Heart Rhythm Association [6], all of which have retained the 
term non-Vitamin K antagonist oral anticoagulants (NOACs).  
A pharmacoepidemiological study of DOAC prescribing in primary care in the UK from 
2009 to 2015 highlighted substantial increases in prescribing over the study period. By 
2015, DOACs had surpassed warfarin as the oral anticoagulants of choice, particularly for 
the management of AF [7]. While there is an extensive evidence base of systematic 
reviews and meta-analyses demonstrating effectiveness and safety of DOACs for a range 
of indications and patient groups, to date no systematic reviews have been published on 
clinicians’ preferences, values or experiences with DOACs.  Given current prescribing 
levels and the expected trend towards increasing use and now being recommended first 
line for several indications [3-7], there is a need for pooled data on their perspectives. 
The aim of this systematic review was to critically appraise, synthesise and present the 
available evidence of clinicians’ views and experiences of the use of DOACs for the 
management of non-valvular AF.  
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Methods 
A systematic review protocol was developed according to the standards of PRISMA-P 
(Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) [8], and 
subsequently registered with PROSPERO (International Prospective Register of 
Systematic Reviews) at the University of York, United Kingdom (UK) [9].  
Inclusion and exclusion criteria  
Studies were included if they reported the views and/or experiences of either doctors, 
nurses or pharmacists on any individual DOAC or as a pharmacological group. All 
primary research studies of any design (quantitative, qualitative or mixed), published in 
English from January 2006 (launch of DOACs) to July 2017 were included. Conference 
abstracts and proceedings were excluded due to the lack of detail for quality assessment 
and data extraction. 
Search strategy  
The following databases were searched: Cumulative Index to Nursing & Allied Health 
Literature (CINAHL), International Pharmaceutical Abstracts, Medline and PsycARTICLES. 
Search terms (title, abstract, text, keyword) were: (clinician* OR doctor* OR surgeon* 
OR general practitioner* OR family doctor* OR physician* OR pharmacist* OR nurse* OR 
health professional* OR healthcare Professional* OR health carer* OR practitioner* OR 
prescriber* OR healthcare provider*) AND (new oral anticoagulant* OR novel oral 
anticoagulant* OR direct oral anticoagulant* OR non-vitamin K oral anticoagulant* OR 
dabigatran OR rivaroxaban* OR apixaban OR edoxaban) AND (experience* OR use* OR 
utility* OR evaluation* OR audit* OR behav* OR knowledge OR satisfaction OR skill* OR 
practice* OR practise* OR belief* OR attitude* OR view* OR opinion* OR perspective*). 
The reference lists of all identified papers were reviewed to identify additional studies. A 
random sample of 10% of titles, abstracts and full papers were screened by an 
independent researcher to confirm reliability of the screening process.  
Quality assessment, data extraction and synthesis  
All studies were assessed for quality assessment by two independent reviewers and a 
third consulted if any disagreements. For quantitative, observational studies and adapted 
STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) 
checklist was used [10], with an adapted COREQ (Consolidated Criteria for Reporting 
Qualitative Research) checklist for qualitative studies [11]. A piloted tool was used by 
two independent researchers to extract data of: study aim; country; setting, study 
design; participants; use of any theory in data collection and analysis; number of 
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participants; and key findings. Given the differences in data collected, quantitative 
findings were synthesised using a narrative approach. It had been intended that 
qualitative research would be pooled with aggregation or synthesis of findings to 
generate a set of statements that represented that aggregation; however, only one 
qualitative study was identified.  
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Results 
Searching 
The PRISMA flowchart is given in Figure 1. Removal of duplicates and screening of the 
titles reduced the number of papers from 979 to 394. Screening of the abstracts reduced 
this number to 195 and a further 186 removed following screening of the full papers. 
Reasons for exclusion of full papers included: review articles (systematic and narrative, 
n=41); editorials and opinion papers (n=36); no data relating to DOACs  (n=36); 
clinician reports of patient registries or databases (n=38); and primary research data on 
patients’ views and experiences only (n=35). Nine papers were retained for quality 
assessment plus one further paper identified from screening the reference lists of the 
nine papers. Of the ten papers, nine were quantitative (cross-sectional survey based 
methodology) and one qualitative (semi-structured interview method, no methodology 
stated).  
Quality assessment  
Quality assessment is given in Tables 1 and 2 for the quantitative studies and the one 
qualitative study respectively. For the quantitative studies, key areas of strength were 
the clarity of statement of study aims and description of participants, settings and 
outcome measures. Fewer studies provided detailed information on sampling strategies, 
and justification of sample size was only provided in two studies [12,15]. There was also 
a lack of detail provided on the approaches to recruitment. Similarly, very few described 
any approach to questionnaire development, item selection and pre-testing. Notably 
theory was not used to support development of questionnaire domains and items in any 
of the studies reviewed.    
While the one qualitative study involved semi-structured interviews, the study 
methodology (e.g. phenomenology, grounded theory) was not stated. Key areas of 
strength were aspects of research trustworthiness (e.g. double coding of interview 
transcripts and representing the participants’ voices through illustrative quotes). Areas of 
weakness were: the lack of consideration of the researcher perspective, no theory to 
underpin the development of the interview schedule or coding framework, and the 
limited sample size of seven which reduced the potential of obtaining data saturation.  
All studies were, however, considered to be of sufficient quality to be included within the 
data extraction phase. 
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Data extraction 
Data extraction of these ten studies is given in Tables 3 and 4. Nine studies were of a 
cross-sectional survey methodology conducted largely in Europe (n=7) and North 
America (n=3), with one study reporting data from Europe and North America. DOACs as 
a group were the focus of eight studies with one specifically related to dabigatran. 
Populations studied were described as: GPs (n=4), centres of research networks (n=3), 
cardiologists (n=3), general internists (n=2), hospital doctors (n=1), members of 
associations (n=1) and non-medical prescribers (n=1), with many of the studies 
reporting data from more than one group. None of the studies referred to any theories 
(e.g. psychological, organisational) considered as part of data collection tool 
development. The number of respondents ranged from 38 to 450 (total of 1246) with 
response rates of 9% to 35.9%. Only three studies quoted a response rate.  
The one qualitative study reported data from seven physicians in the USA. There was no 
description of any theory used in the stages of data generation, analysis or 
interpretation. 
Data synthesis 
The heterogeneity of the quantitative studies in terms of study aims and specific 
domains and items within the questionnaires limited the approach to data synthesis. 
Given that there was only one qualitative study, meta-synthesis of the qualitative 
findings was not possible. Table 5 gives the synthesis of the findings from the nine 
quantitative studies, highlighting the lack of homogeneity in the specific elements 
studied in each. While only one quantitative study reported factors influencing DOAC use 
[12], this was also the aim of the one qualitative study [21]. The quantitative study 
highlighted the top three factors determining eligibility for dabigatran in warfarin naïve 
patients as: cost to the patient (reported by 25% of respondents); non-compromised 
renal function (21%); and CHADS2 score (18%). For patients on warfarin, these were: 
having an unstable INR (37%); patient affordability (9%); and missed appointments 
(17%) [12]. Some of these also emerged in the qualitative study in terms of risks to the 
patient, patient convenience and cost, with additional themes of the clinician willingness 
to try new agents and their experience of these agents [21].  
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Six studies reported data on clinician preference for DOACs compared to warfarin [12-
14, 17, 18, 20]. In a study of 65 cardiologists and general internists, cardiologists were 
significantly more comfortable than general internists in prescribing DAOCs over 
warfarin, as were those who had prescribed DOACs in more than ten patients [14]. While 
DOACs were not the main focus of a study of 45 research network centres, there were 
differences across centres in the use of DOACs first line [13]. Data from a further study 
of 38 of these centres identified that 33.3% of respondents preferred DOACs to warfarin, 
with 48.5% considering them to be equally safe [17]. Similar safety data were reported 
in a study of 227 cardiologists and GPs, with over 80% considering DOACs as effective 
as warfarin [14]. Rivaroxaban was selected as first line oral anticoagulant by 178 
physicians, with only 12% opting for warfarin [18]. DOACs were also selected first line 
by 70% of 53 GPs attending a medical congress [20]. Key reasons reported in these 
studies for DOAC preference were the perceptions of evidence of effectiveness equivalent 
or superior to warfarin and superior safety. While DOACs were largely considered more 
appropriate in warfarin naïve patients, there was less support for switching patients 
established on warfarin.  
DOAC associated bleeding was a key issue, being observed in patients of 40% (n=90) of 
cardiologists and GPs [14]. In the preceding two years, 53 GPs had seen 1.9 ± 2.87 
(range 0–14) bleeding complications in patients prescribed DOACs, of which 0.5 ± 0.95 
(range 0–5) were referred to hospital [20]. Two studies reported the need for guidelines 
to support the use of DOACs in the management of AF, with respondents welcoming 
specific guidance on the management of DOAC induced bleeding [13,14].  
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Discussion 
This systematic review has highlighted that relatively few studies have reported clinician 
perspectives; nine cross-sectional surveys and one qualitative study were included in the 
review, with marked heterogeneity in the specific outcomes reported. In those studies 
reporting preference, DOACs were first choice over warfarin in naïve patients based on 
perceptions of evidence of effectiveness equivalent or superior to warfarin and superior 
safety. Other advantageous factors were in those with an unstable INR and likely to miss 
appointments. There were, however, concerns relating to their experiences of observed 
bleeding rates.  
One key strength of this systematic review was conducted according to best practice and 
reported in accordance with the PRISMA (Preferred Reporting Items for Systematic 
Review and Meta-Analysis) standards [22]. However, the generalisability or 
transferability of review findings to other countries or cultures may be limited given that 
all were conducted in either Europe or the USA. None of the quantitative studies had 
response rates over 40%, increasing the likelihood of response bias thus threatening 
internal validity. Furthermore, to date, only one qualitative study and no mixed-methods 
studies have been reported.  
Ours is the first systematic review which has focused on clinicians’ perspectives of 
DOACs which is rather surprising given the vast number of systematic reviews and meta-
analyses of effectiveness and safety. While each of the studies was generally of good 
quality, reporting could be enhanced by referring to design specific checklists which are 
now hosted on the EQUATOR (Enhancing the QUAlity and Transparency Of health 
Research) website. In particular, none of the studies reporting influences on prescribing 
options were grounded in theories of behaviour. Frameworks such as the Theoretical 
Domains Framework, which is derived from 33 psychological theories and 128 theoretical 
constructs, which are organised into 14 overarching domains, would provide a more 
comprehensive approach thus facilitating development of behaviour change interventions 
if required [23].   
Despite the limited number of studies, review findings have highlighted a number of 
issues which merit further consideration given current prescribing levels and likely future 
increases [7]. Positive factors influencing selection of a DOAC over warfarin, such as 
patient convenience, reduced risk and stability of INR reflect DOAC clinical 
pharmacological properties relating to mechanism of action eliminating the need for INR 
testing [2]. There appeared to be awareness of the evidence base of DOAC effectiveness 
and safety, although also a stated need for practice guidelines, particularly to support 
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management of over-anticoagulation and anticoagulant reversal. Given that 
idarucizumab is now licensed for use and is indicated to reverse dabigatran in patients 
with life threatening haemorrhage or need for urgent surgery [24], it is likely that these 
issues will resolve in the near future.  
The findings of our systematic review provide some evidence of the need to support 
decision-making and management of those patients already established on warfarin and 
how to transfer safely to DOACs if appropriate. The recently updated 2018 European 
Heart Rhythm Association Practical Guide on the use of DOACs in non-valvular AF 
provides much needed protocols for tapering, stopping and switching from DOACs to 
warfarin and vice versa [6].   
Views of patients should also be central to decision-making around choice of oral 
anticoagulants. A systematic review of patients’ values and preferences for DOACs 
versus warfarin generated heterogeneous findings, highlighting the need for focusing on 
patients’ individual values and preferences [25]. A further systematic review reported 
that stroke risk reduction and a moderate increase in the risk of bleeding were the most 
important attributes for patients when deciding between DOACs and warfarin [26]. The 
need to focus on the patient perspective is increasingly highlighted within local, national 
and international guidelines [3-6]. 
Forty percent of respondents in one study included in our systematic review reported 
observed bleeding complications in those prescribed DOACs [14]. While the incidence 
and severity of bleeding were not reported, several systematic reviews have concluded 
that the risk of major bleeding is generally equivalent to or less than that with warfarin, 
there is a need for further high quality studies [27-29]. There is therefore a need for 
intensive patient monitoring and reporting of events to national and international 
pharmacovigilance schemes. 
Given the limited evidence base, there is a need for more robust and rigorous research 
which systematically explores experiences, views and behaviours of clinicians, with the 
overall aim of optimising appropriate use of DOACs. Mixed quantitative-qualitative 
approaches are recommended to allow, specifically an explanatory, sequential mixed 
methods design characterised by the collection and analysis of quantitative data followed 
by generation and analysis of qualitative data. The qualitative findings will generate in-
depth and rich data to assist in exploring, explaining and interpreting the statistically 
based results of the quantitative element. 
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Conclusion 
This systematic review has identified a limited evidence base of clinicians’ views and 
experiences and a need for further research. While DOACs were first choice over warfarin 
in naïve patients based and perceptions being advantageous in those with an unstable 
INR and likely to miss appointments, there is a need to support prescribing and 
specifically the management of over-anticoagulation.  
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Table 1. Quality assessment of the nine cross-sectional studies using adapted STROBE criteria  
 
STROBE criteria Huang et 
al., 2013 
[12] 
 
Lip et 
al., 
2013 
[13] 
Wutzler et 
al., 2014 
[14] 
Faraoni, et 
al., 2014 
[15] 
Potpara et 
al., 2014 
[16] 
 
 
Larsen et 
al., 2015 
[17] 
Andrade 
et al., 
2016 [18] 
Olaiya et 
al., 2016 
[19] 
Sauter et 
al., 2016 
[20] 
 
Aim  State specific aim/ 
objectives 
Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Yes  
Methods 
Setting Describe the 
setting, locations, 
and relevant dates 
Yes 
 
 Partly  Yes   Yes  Partly  Partly  Partly  Partly Partly 
Participants  Give the eligibility 
criteria, and the 
sources and 
methods of 
participant 
selection 
Partly Partly  Partly  Partly  No  No  Partly  Partly Partly 
Variables Clearly define all 
outcomes 
Partly Partly  Partly  Partly Partly  Partly  Yes    Yes  Partly 
Data sources For each variable 
of interest, give 
sources of data 
and details of 
methods of 
assessment  
Yes  Partly  Partly Partly Partly  Partly  Partly   Yes   Partly  
Bias Describe any 
efforts to address 
potential sources 
of bias 
Partly No  No  No  No  No   Partly  Partly No 
Study size Explain how the 
study size was 
arrived at 
Partly Partly  No  Yes  Partly  Partly  Partly  Partly No 
 
Quantitative 
variables 
Explain how 
quantitative 
variables were 
handled in the 
analyses 
Yes  Partly  No   Yes 
 
 Partly  Partly  Yes  Yes  Partly 
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Statistical 
methods 
(a) Describe all 
statistical methods 
Partly Partly  No  Yes 
 
Partly  Partly Partly  Partly No 
(b) Describe any 
methods used to 
examine 
subgroups and 
interactions 
Partly N/A No Yes  N/A N/A No  Partly N/A  
Participants (a) Report 
numbers of 
individuals at each 
stage of study 
 Yes  N/A Partly Yes  Yes Yes 
 
Partly  Partly  Yes 
(b) Give reasons 
for non-
participation at 
each stage 
N/A No  No  Partly No  No N/A N/A N/A 
Descriptive 
data 
(a) Give 
characteristics of 
study participants  
Yes 
 
 No  Partly Yes  Partly  Partly   Partly  Partly  Yes  
(b) Indicate 
number of 
participants with 
missing data for 
each variable of 
interest 
 N/A No  No  Partly No  No  No  Yes  Yes  
Outcome 
data 
Report numbers of 
outcome events or 
summary 
measures 
Yes   Yes  Partly Yes  Partly  Partly Yes  Yes  Yes  
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Table 2. Quality assessment of the qualitative study using adapted COREQ criteria   
 
Criteria  Kirley et al., 
2016 [21] 
Aim State specific aim/objectives Yes 
Personal Characteristics 
  
(a) Interviewer/facilitator. Which author/s conducted the interview or focus group? Yes  
   
(b) Interviewer characteristics. What characteristics were reported about the 
interviewer/facilitator? 
No 
Methodological orientation 
and Theory  
What methodological orientation was stated to underpin the study? No  
Sampling  How were participants selected?  Yes  
Method of approach  How were participants approached?  No  
Sample size  How many participants were in the study? Yes  
Non-participation  How many people refused to participate or dropped out? Reasons? No  
Setting of data collection Where were the data collected? No 
Description of sample  What are the important characteristics of the sample?  Partly 
Interview guide Were questions, prompts, guides provided by the authors? Was it pilot tested? Partial 
Audio/visual recording  Did the research use audio or visual recording to collect the data? Yes  
Field notes  Were field notes made during and/or after the interview or focus group? No 
Data saturation  Was data saturation discussed? Partly 
Number of data coders  How many data coders coded the data? Yes  
Description of the coding tree  Did authors provide a description of the coding tree? No  
Derivation of themes Were themes identified in advance or derived from the data? Yes 
Quotations presented  Were participant quotations presented to illustrate the themes / findings? Was each 
quotation identified?  
Yes  
Data and findings consistent  Was there consistency between the data presented and the findings? Yes  
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Table 3. Data extraction of the nine quantitative studies 
 
Authors/years  Aim(s) Country/ 
setting (if 
stated) 
Design  Participants  Theory 
applied  
Number of 
participants 
(response 
rate) 
Key findings  
Huang et al., 2013 
[12] 
 
 
To identify factors 
that influence 
doctors’ decisions to 
prescribe 
dabigatran. To 
compare levels of 
comfort with 
prescribing 
dabigatran between 
healthcare 
professionals 
USA 
(California) 
Cross- 
sectional 
survey  
 
Cardiologists 
and general 
internists 
 
No  65/181 (35.9%) 
responses; 13 
cardiologists, 51 
general 
internists (one 
not stated) 
 
In warfarin naive patients, the main 
influences were: affordability for 
patient; renal function; and CHADS2 
score  
 
For those prescribed warfarin, were: 
unstable INR; affordability for patient; 
missed appointments 
 
Cardiologists preferred to prescribe 
dabigatran more often compared to 
general internists who were less 
comfortable prescribing cardiologists 
 
Lip et al., 2013 
[13] 
To assess European 
clinical practice in 
relation to the use 
of oral 
anticoagulants for 
stroke prevention in 
AF with particular 
focus on DOACs as 
a management 
strategy 
 
European 
countries 
 
Cross-
sectional 
survey 
Participating 
centres of the  
Electro-
physiology 
Research 
Network 
No  No overall 
response rate 
given. 
Responses from 
45 centres, 
66.7% were 
university 
hospitals, 22.2% 
private hospitals, 
11.1% others 
 
There were clear practice differences 
evident, and also the need for greater 
adherence to the guidelines, especially 
since guideline adherent management 
results in better outcomes 
 
Reassuring information on current 
practice in Europe for the use of 
DOACs for stroke prevention in AF was 
evident, although VKA use remained 
dominant in some clinical scenarios 
 
Wutzler et al.,  
2014 [14] 
To access 
physicians' 
acceptance and 
appreciation of the 
DOACs in a real-life 
community setting 
 
Germany Cross- 
sectional 
survey 
Cardiologists 
and GPs 
No  227 responses 45.4% considered DOACs and VKAs to 
be equally safe and 82.8% to be 
equally effective 
  
Bleeding complications following the 
use of DOACs were observed by 
39.6% 
Faraoni et al., 
2014 [15] 
To assess: 
physicians’  
Europe and 
USA 
Cross–
sectional 
survey 
All members of 
Society of 
No  450/5262 (9%) 
but only 117 
completed all 
29% stated no guidelines on DOAC 
reversal used in their institution while 
28% used local 
 This article is protected by copyright. All rights reserved. 
level of knowledge 
about perioperative 
management of 
patients treated 
with 
NOACs; current 
practices; and 
perspectives 
needed to improve 
the management 
of patients treated 
with NOACs 
 
 Cardiovascular 
Anesthesi- 
ologists and 
European 
Association of 
Cardiothoracic 
Anaesthesi-
ologists 
sections of the 
questionnaire 
 
guidelines, 35% national and 14% 
international 
guidelines   
 
46% stated that no agreement had 
been reached in their institution on 
the use of guidelines and 18% 
believed that no guidelines had been 
established due to the lack evidence 
97% thought guidelines were needed 
to improve management generally 
and particularly for monitoring (69%) 
and reversal (73%) 
Potpara et 
al.,2014 [16] 
To assess  the 
European practice 
of  treatment of 
patients with non-
valvular AF 
presenting with 
an Acute Coronary 
Syndrome 
European 
countries  
Cross-
sectional 
survey  
European Heart 
Rhythm 
Association   
electrophysiolo
gy research 
network 
participating 
centres  
 No  No overall 
response rate 
given. 
Responses from 
47 centres, 
85.4% university 
hospitals. 
Cardiac surgery 
available in 
82.9% 
 
Key findings were two important areas 
of uncertainty regarding: the optimal 
composition and duration of 
antithrombotic therapy with multiple 
drugs; and the optimal regimen(s) of 
DOACs 
 
Larsen et al., 2015 
[17] 
To assess the 
clinical practice in 
relation to the use 
of OAC therapy for 
patients with AF in 
Europe, in different 
clinical situations 
 
Multiple 
countries in 
Europe. 
University 
hospitals, 
private 
hospitals, 
other sites  
 
Cross-
sectional 
survey 
Participating 
centres of the  
Electro-
physiology 
Research 
Network 
No  No overall 
response rate 
given. 
Responses from 
38 centres, 
65.8% were 
university 
hospitals, 21.0% 
private hospitals, 
13.2% others. 
33.3% stated that DOACs were their 
preferred treatments 
 
48.5% considered DOACs to be 
equally effective compared to VKAs 
  
12% preferred using DOACs for dual 
antiplatelet therapy in AF patients 
undergoing percutaneous coronary 
intervention 
Andrade et al., 
2016 [18] 
To determine the 
attitudes, values, 
preferences, and 
experience of 
physicians 
prescribing OAC 
therapy for non-
valvular AF 
 
Canada Cross-
sectional 
survey 
GPs, 
cardiologists, 
internal 
medicine 
specialists 
 
No  178 physicians 
were randomly 
selected and 
responded 
Preferences regarding OAC therapy 
largely focused on characteristics 
related to safety and efficacy 
 
Physicians stated preferred 
anticoagulant was apixaban based on 
properties and blinded to specific 
drugs (61%). However, 49% of 
physicians spontaneously stated 
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rivaroxaban as their preferred agent 
(vs 25% apixaban) 
 
Olaiya et al., 2016 
[19] 
To determine 
healthcare 
professionals’ level 
of awareness of the 
DOACs and to 
examine their 
understanding of 
the effects of 
DOACs on a 
hypothetical patient 
 
Scotland  
 
Cross-
sectional 
survey  
Hospital 
doctors, GPs, 
non-medical 
independent 
prescribers 
(nurses and 
pharmacists)  
No  143 practising 
clinicians and 
non-medical 
prescribers  
responded 
There were significant differences in 
awareness of DOACs. 88%, 80% and 
50%, respectively, recognised 
rivaroxaban, dabigatran, 
and apixaban to be DOACs 
 
When provided with a routine clinical 
situation, 
only 13.5%, 17.5% and 16.8% 
respondents respectively recognised 
that the hypothetical patient was 
anticoagulated, and only 55–58% 
recognised that it was unsafe to 
proceed with an invasive procedure 
Sauter et al., 2016 
[20] 
To investigate 
physicians’ 
preferences of 
DOACs, prevalence 
and choice of 
DOACs, clinical 
follow up including 
follow up blood 
testing and bleeding 
complications 
Switzerland   Cross-
sectional 
survey 
GPs attending 
a GP 
emergency 
medicine 
congress 
No  53 GPs 
participated 
(response rate 
40.8%)  
Participants treated 32.7% (±19) of 
their patients requiring oral 
anticoagulation with DOACs 
 
New AF patients who had started oral 
anticoagulation received DOACs from 
70% but most would not switch 
patients from warfarin to DOACs 
  
In the preceding 2 years, GPs had 
seen 1.9 (±2.87) bleeding 
complications in patients with DOACs 
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Table 4. Data extraction of the one qualitative study 
 
Authors/years  Aim Country   Design  Participants  Theory 
applied  
Key findings  
Kirley et al., 
2016 [21] 
A qualitative study of 
physicians’ decision-
making processes 
regarding anticoagulation 
management in AF, with 
a specific focus on the 
role of DOACs 
USA 
 
Semi-
structured 
interviews 
A total of seven 
physicians, 
three family 
physicians, one 
internist, two  
cardiologists, 
one cardiologist 
sub-specialising 
in electro-
physiology 
No Four themes emerged: the likelihood of 
prescribing DOACs depended upon their 
willingness to try new medications and 
experience; they typically balanced the benefits 
and risks of anticoagulation in AF patient; 
patient convenience and preferences, as well as 
physician convenience, were important; and 
concerns regarding out-of-pocket cost of DOACs 
deterred many from prescribing 
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Table 5. Synthesis of the key findings of clinicians’ views and experiences from the nine quantitative studies  
Clinician reported… Huang et al., 
2013 [12] 
 
Lip et al., 
2013 [13] 
Wutzler et 
al., 2014 
[14] 
Faraoni, et 
al., 2014 
[15] 
Potpara et 
al., 2014 
[16] 
 
 
Larsen et al., 
2015 [17] 
Andrade et 
al., 2016 
[18] 
Olaiya et al., 
2016 [19] 
Sauter et al., 
2016 [20] 
 
factors influencing 
DOAC use 
 
Cost, renal 
function, 
CHADS2 score, 
unstable INR, 
patient 
attendance 
 
Not reported Not reported Not reported Not reported Not reported Not reported Not reported Easier 
dosing, 
fewer blood 
tests, follow-
up and 
bleeding 
events  
preference over warfarin Cardiologists 
preferred more 
than general 
internists 
 
Cardiologists 
more 
comfortable   
Clear 
practice 
differences 
across 
centres, 
warfarin 
remained 
dominant  
Majority 
considered 
equally 
effective, 
half equally 
safe 
 
Not reported Not reported Third 
preferred 
DOACs, half 
considered 
equally safe 
Half selected 
rivaroxaban 
as their 
preferred 
oral 
anticoagulant  
Not reported New patients 
started 
DOACs, less 
likely to 
change 
stabilised on 
warfarin 
 
comments on guidelines 
 
Not reported Need for 
greater 
adherence to 
AF 
guidelines in 
general 
 
Not reported Need for 
guidelines 
on use of 
DOACs and 
reversal 
specifically  
Not reported Not reported Not reported Not reported Not reported 
issues in use of DOACs 
 
Not reported Not reported Almost 40% 
had 
observed 
bleeding 
complication 
Not reported Need for 
evidence on 
optimal 
regimens 
Not reported Not reported Not reported Bleeding 
issues 
reported by 
all 
respondents 
 
Poor 
clinician 
recognition 
of specific 
DOACs as 
anti- 
coagulants 
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Figure 1: Study selection process (PRISMA flow diagram)  
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